Immunologic Disease
8
2
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Gulf Long-Term Follow-Up Study
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases
Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
Endocrine, Metabolic, Cardiovascular and Immunological Aspects of Sex Chromosome Abnormalities in Relation to Genotype
Interaction Between Immune Cells and Bacteria Associated With Periodontitis
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Consequences of Conjugal Bereavement in Adults